Heartburn Drugs: Medications That Cause It and Medications That Treat It

Drugs That Cause Heartburn: The Pharmacologic Offenders

Multiple drug classes provoke heartburn through two distinct mechanisms: lowering the resting tone of the lower esophageal sphincter (LES) or causing direct chemical irritation to esophageal and gastric mucosa. Recognizing these medications is the first step in resolving drug-induced symptoms.

LES-relaxing medications include calcium channel blockers (amlodipine, nifedipine), nitrates, theophylline, anticholinergics, and benzodiazepines. A systematic review published in the American Journal of Gastroenterology found that calcium channel blockers increased reflux episodes measured by 24-hour pH monitoring in 15-20% of treated patients [1]. Nifedipine specifically reduced LES pressure from a mean of 15 mmHg to 5 mmHg in controlled manometric studies.

Direct mucosal irritants include NSAIDs (ibuprofen, naproxen, aspirin), bisphosphonates (alendronate, risedronate), potassium chloride tablets, tetracycline antibiotics (especially doxycycline), and iron supplements. NSAIDs inhibit prostaglandin synthesis, reducing the protective mucous layer. A population-based study of 11,945 NSAID users demonstrated a 1.5-fold increased risk of weekly heartburn symptoms compared to non-users [2].

Bisphosphonates deserve special attention. Alendronate can cause esophageal erosions, strictures, and (rarely) perforation. The FDA requires that patients take oral bisphosphonates with a full glass of water, remain upright for 30-60 minutes afterward, and avoid lying down [3]. Patients who cannot comply with these instructions should receive intravenous zoledronic acid instead.

Doxycycline causes pill esophagitis in approximately 1 in 500 courses, typically when swallowed with insufficient water or taken immediately before sleep [4]. The capsule dissolves on the esophageal mucosa, releasing acid directly into tissue.

Proton Pump Inhibitors: First-Line Treatment for Frequent Heartburn

PPIs suppress gastric acid secretion by irreversibly blocking the hydrogen-potassium ATPase enzyme on parietal cells. They are the most potent acid-suppressive agents available and the treatment of choice for erosive esophagitis, frequent heartburn (two or more episodes per week), and GERD complications.

Six PPIs are currently marketed in the United States: omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, and dexlansoprazole. All achieve comparable healing rates at standard doses. The landmark study by Kahrilas et al. (N=5,241) demonstrated that esomeprazole 40 mg healed erosive esophagitis in 93.7% of patients at 8 weeks versus 84.2% for omeprazole 20 mg [5]. The clinical difference at standard doses is modest. Most guidelines, including the American College of Gastroenterology 2022 update, recommend choosing a PPI based on cost and availability rather than perceived superiority [6].

Timing matters. PPIs should be taken 30-60 minutes before the first meal of the day because they only inhibit actively secreting proton pumps. Taking a PPI after eating or at bedtime reduces bioavailability by 30-50%. Dexlansoprazole is the exception: its dual delayed-release formulation allows dosing regardless of meal timing.

Standard PPI courses for uninvestigated heartburn run 4-8 weeks. After symptom resolution, the ACG recommends attempting step-down to the lowest effective dose or switching to on-demand therapy [6]. Abrupt discontinuation after prolonged use (greater than 8 weeks) can produce rebound acid hypersecretion lasting 2-4 weeks.

H2-Receptor Antagonists: The Middle Ground

H2 blockers (famotidine, cimetidine, nizatidine) reduce acid secretion by 60-70% by blocking histamine receptors on parietal cells. They work within 30-60 minutes and provide relief lasting 6-12 hours. Their primary advantage over PPIs is rapid onset; their primary disadvantage is tachyphylaxis (tolerance) developing within 2-6 weeks of continuous use.

Famotidine 20 mg twice daily is the most commonly prescribed H2 blocker. A Cochrane meta-analysis of 34 trials found that H2 blockers healed erosive esophagitis in only 50% of patients at 12 weeks, compared to 80-90% with PPIs [7]. For this reason, H2 blockers are now recommended for mild, intermittent heartburn or as add-on nocturnal therapy in patients with incomplete PPI response.

The 2020 FDA withdrawal of ranitidine (Zantac) due to NDMA contamination removed the most widely used H2 blocker from the market [8]. Famotidine contains no detectable NDMA and remains the H2 blocker of choice.

A practical role for H2 blockers: bedtime dosing for nocturnal breakthrough symptoms in patients already on morning PPI therapy. A crossover study by Peghini et al. showed that famotidine 20 mg at bedtime reduced nocturnal gastric acid breakthrough from 75% to 26% of the recording period [9]. Tolerance develops after approximately 2 weeks of nightly use, so intermittent dosing (3-4 nights per week) may preserve efficacy longer.

Antacids and Alginate Formulations: Immediate But Brief Relief

Antacids (calcium carbonate, magnesium hydroxide, aluminum hydroxide) neutralize existing gastric acid on contact. They provide the fastest symptom relief of any heartburn treatment (onset within 5 minutes) but the shortest duration (30-90 minutes). They do not heal esophageal erosions or prevent future acid secretion.

Calcium carbonate (Tums) delivers 200-400 mg of elemental calcium per tablet, which makes it a reasonable supplemental calcium source. Aluminum-containing antacids cause constipation; magnesium-containing antacids cause diarrhea. Combination products (Maalox, Mylanta) attempt to balance these effects.

Alginate-antacid combinations (Gaviscon Advance, available OTC in many countries) form a physical raft on top of gastric contents that prevents acid from reaching the esophagus. A randomized trial by Reimer et al. (N=110) demonstrated that sodium alginate was non-inferior to omeprazole 20 mg for symptom control in patients with moderate, non-erosive reflux disease over 4 weeks [10]. This positions alginate formulations as a viable first step before escalating to acid-suppressive therapy.

The postprandial acid pocket, a pool of unbuffered acid sitting atop food in the proximal stomach, is the target of alginate therapy. Alginate displaces this pocket downward, reducing the number of acid reflux episodes by roughly 50% in pH-impedance studies [11].

Potassium-Competitive Acid Blockers: The Newest Class

Vonoprazan, a potassium-competitive acid blocker (P-CAB), received FDA approval in 2023 for erosive esophagitis. Unlike PPIs, vonoprazan inhibits proton pumps regardless of their activation state, achieving faster and more complete acid suppression from the first dose.

The PHALCON-EE trial (N=1,024) compared vonoprazan 20 mg daily to lansoprazole 30 mg daily for erosive esophagitis healing. At 8 weeks, vonoprazan achieved 92.9% healing for LA grade C/D esophagitis versus 86.5% for lansoprazole (P=0.014) [12]. The difference was most pronounced in severe disease.

Vonoprazan does not require pre-meal dosing and has no food effect on absorption. Its half-life is approximately 9 hours. Current guidelines have not yet positioned vonoprazan relative to PPIs in treatment algorithms, but it represents an option for patients with persistent symptoms despite optimized PPI therapy or those who struggle with pre-meal dosing requirements.

Managing Drug-Induced Heartburn Without Stopping Necessary Medications

Stopping an offending medication is not always feasible. Patients on chronic NSAIDs for arthritis, calcium channel blockers for hypertension, or bisphosphonates for osteoporosis need strategies to minimize heartburn without sacrificing disease management.

For NSAID users who cannot discontinue therapy, co-prescription of a PPI reduces the risk of peptic ulcers by 80% and meaningfully reduces heartburn symptoms. The ASTRONAUT trial demonstrated that esomeprazole 20 mg daily prevented NSAID-associated ulcers in 95% of patients over 6 months versus 68% with ranitidine 300 mg [13]. COX-2 selective NSAIDs (celecoxib) cause fewer GI symptoms than nonselective NSAIDs but still warrant gastroprotection in high-risk patients (age over 65, history of ulceration, concurrent anticoagulant use).

For calcium channel blocker users, dihydropyridines (nifedipine, amlodipine) relax the LES more than non-dihydropyridines (diltiazem, verapamil). Switching within class or to an alternative antihypertensive (ACE inhibitor, ARB) may resolve symptoms without adding acid-suppressive therapy.

For bisphosphonate users experiencing esophageal symptoms, switching from daily oral alendronate to weekly dosing reduces mucosal exposure. If symptoms persist, transitioning to monthly ibandronate or annual IV zoledronic acid eliminates esophageal risk entirely [3].

"Drug-induced GERD symptoms are underrecognized in clinical practice. A thorough medication review should precede any escalation of acid-suppressive therapy." This principle, articulated in the American Gastroenterological Association 2022 clinical practice update, underscores that pharmacologic heartburn treatment should not bypass the question of whether another drug is causing the problem [14].

When Heartburn Medications Fail: Diagnostic and Therapeutic Escalation

Persistent heartburn despite 8 weeks of optimized PPI therapy (double dose, correct timing, confirmed adherence) occurs in 10-40% of GERD patients. This warrants investigation beyond empiric acid suppression.

Ambulatory 24-hour pH-impedance monitoring, performed off PPI therapy, distinguishes true acid reflux from functional heartburn. The Lyon Consensus defines pathologic acid exposure as time with pH <4 exceeding 6% of the total recording period [15]. Patients with normal acid exposure but symptom correlation may have esophageal hypersensitivity, a condition treated with neuromodulators (tricyclic antidepressants, SSRIs) rather than further acid suppression.

Upper endoscopy identifies erosive esophagitis, Barrett's esophagus, eosinophilic esophagitis, and strictures. The ACG recommends endoscopy for patients with alarm features: dysphagia, odynophagia, unintentional weight loss, GI bleeding, or symptoms persisting despite PPI therapy [6].

High-resolution esophageal manometry excludes motility disorders (achalasia, distal esophageal spasm) that can mimic heartburn. These conditions require entirely different treatment approaches, including pneumatic dilation or per-oral endoscopic myotomy for achalasia.

Comparative Efficacy: Choosing the Right Drug for the Right Patient

The hierarchy of acid-suppressive potency is clear: PPIs/P-CABs > H2 blockers > antacids. Selection depends on symptom frequency, severity, and the presence of mucosal disease.

For infrequent heartburn (fewer than 2 episodes per week), antacids or on-demand H2 blockers suffice. A single dose of famotidine 20 mg before a known dietary trigger (spicy food, alcohol, large meals) prevents symptoms in most patients.

For frequent heartburn (2 or more episodes per week) without endoscopic evaluation, an empiric 4-8 week PPI trial is appropriate. Response to PPI therapy is itself a diagnostic clue: complete resolution suggests acid-mediated disease, while partial or no response warrants further investigation.

For confirmed erosive esophagitis (LA grade B or higher), PPIs or vonoprazan for 8 weeks followed by maintenance therapy at the lowest effective dose represents standard care. Discontinuation leads to relapse in 80-90% of patients with grade C/D esophagitis within 6 months [5].

"The goal of GERD treatment is the minimum effective therapy that controls symptoms and heals mucosal disease." This statement from the ACG 2022 guidelines should guide every prescribing decision [6].

Long-Term Safety Considerations for Acid-Suppressive Therapy

PPI safety concerns have generated substantial media attention but limited high-quality evidence of causation. Observational studies have associated long-term PPI use with increased risks of C. difficile infection (RR 1.7), hip fracture (RR 1.2-1.4), chronic kidney disease, and hypomagnesemia [16]. Randomized trial data tell a different story.

The COMPASS trial (N=17,598), a randomized controlled trial comparing pantoprazole 40 mg daily to placebo over a median 3.0 years, found no significant increase in pneumonia, fractures, chronic kidney disease, dementia, or cardiovascular events [17]. The only confirmed association was a modest increase in enteric infections (HR 1.33). This remains the largest RCT examining PPI safety.

Practical implications: patients with a clear indication for PPI therapy (erosive esophagitis, Barrett's esophagus, chronic NSAID use with risk factors) should continue treatment without fear of the observational signal. Patients on PPIs for mild symptoms without endoscopic disease should attempt periodic step-down or discontinuation.

H2 blockers carry no significant long-term safety concerns at standard doses. Cimetidine's weak anti-androgen effect (gynecomastia at high doses) makes famotidine the preferred agent for chronic use.

Chronic antacid use is generally safe but can cause milk-alkali syndrome (hypercalcemia, metabolic alkalosis) with excessive calcium carbonate intake exceeding 4-5 g/day of elemental calcium. Aluminum-containing antacids should be avoided in patients with renal insufficiency due to accumulation risk.